N-(2,6-difluorophenyl)-4-(4-(6-(3-(2-methoxyacetamido)prop-1-ynyl)quinazolin-4-ylamino)-2-methylphenoxy)piperidine-1-carboxamide

ID: ALA389457

Chembl Id: CHEMBL389457

PubChem CID: 44426263

Max Phase: Preclinical

Molecular Formula: C33H32F2N6O4

Molecular Weight: 614.65

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  COCC(=O)NCC#Cc1ccc2ncnc(Nc3ccc(OC4CCN(C(=O)Nc5c(F)cccc5F)CC4)c(C)c3)c2c1

Standard InChI:  InChI=1S/C33H32F2N6O4/c1-21-17-23(39-32-25-18-22(8-10-28(25)37-20-38-32)5-4-14-36-30(42)19-44-2)9-11-29(21)45-24-12-15-41(16-13-24)33(43)40-31-26(34)6-3-7-27(31)35/h3,6-11,17-18,20,24H,12-16,19H2,1-2H3,(H,36,42)(H,40,43)(H,37,38,39)

Standard InChI Key:  RCKIDWKUGKLLRU-UHFFFAOYSA-N

Associated Targets(Human)

ERBB2 Tclin Receptor protein-tyrosine kinase erbB-2 (7851 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ERBB2 Tclin Epidermal growth factor receptor and ErbB2 (HER1 and HER2) (186 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 614.65Molecular Weight (Monoisotopic): 614.2453AlogP: 5.15#Rotatable Bonds: 8
Polar Surface Area: 117.71Molecular Species: NEUTRALHBA: 7HBD: 3
#RO5 Violations: 2HBA (Lipinski): 10HBD (Lipinski): 3#RO5 Violations (Lipinski): 2
CX Acidic pKa: 10.30CX Basic pKa: 4.36CX LogP: 4.51CX LogD: 4.51
Aromatic Rings: 4Heavy Atoms: 45QED Weighted: 0.24Np Likeness Score: -1.55

References

1. Lippa B, Kauffman GS, Arcari J, Kwan T, Chen J, Hungerford W, Bhattacharya S, Zhao X, Williams C, Xiao J, Pustilnik L, Su C, Moyer JD, Ma L, Campbell M, Steyn S..  (2007)  The discovery of highly selective erbB2 (Her2) inhibitors for the treatment of cancer.,  17  (11): [PMID:17398092] [10.1016/j.bmcl.2007.03.046]

Source